NantKwest Competitors

NantKwest (NASDAQ:NK) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 21.4% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Fate Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Fate Therapeutics, as reported by MarketBeat.

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 38.88%. Given Fate Therapeutics' higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Fate Therapeutics' revenue, earnings per share and valuation.

NantKwest has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

NantKwest (NASDAQ:NK) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 7.0% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Twist Bioscience's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Twist Bioscience, as reported by MarketBeat.

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Twist Bioscience has a consensus target price of $133.3333, suggesting a potential upside of 0.83%. Given NantKwest's stronger consensus rating and higher possible upside, equities research analysts clearly believe NantKwest is more favorable than Twist Bioscience.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Twist Bioscience's revenue, earnings per share and valuation.

NantKwest has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

NantKwest beats Twist Bioscience on 8 of the 14 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 19.3% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Denali Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Denali Therapeutics, as reported by MarketBeat.

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Denali Therapeutics has a consensus target price of $75.8571, suggesting a potential upside of 45.15%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Denali Therapeutics' revenue, earnings per share and valuation.

NantKwest has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

Denali Therapeutics beats NantKwest on 8 of the 14 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Halozyme Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Halozyme Therapeutics, as reported by MarketBeat.

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Halozyme Therapeutics has a consensus target price of $42.9167, suggesting a potential upside of 0.34%. Given NantKwest's stronger consensus rating and higher possible upside, equities research analysts clearly believe NantKwest is more favorable than Halozyme Therapeutics.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Halozyme Therapeutics' revenue, earnings per share and valuation.

NantKwest has higher earnings, but lower revenue than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats NantKwest on 8 of the 14 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 22.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Adaptive Biotechnologies' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Adaptive Biotechnologies, as reported by MarketBeat.

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Adaptive Biotechnologies has a consensus target price of $61.40, suggesting a potential upside of 51.90%. Given Adaptive Biotechnologies' higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Adaptive Biotechnologies' revenue, earnings per share and valuation.

NantKwest has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

NantKwest (NASDAQ:NK) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Institutional & Insider Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 82.3% of Kodiak Sciences shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 39.3% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NantKwest and Kodiak Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for NantKwest and Kodiak Sciences, as reported by MarketBeat.

NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Kodiak Sciences has a consensus target price of $129.9091, suggesting a potential upside of 19.11%. Given Kodiak Sciences' higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than NantKwest.

Risk & Volatility

NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Earnings and Valuation

This table compares NantKwest and Kodiak Sciences' revenue, earnings per share and valuation.

Kodiak Sciences has lower revenue, but higher earnings than NantKwest. Kodiak Sciences is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.

Summary

Kodiak Sciences beats NantKwest on 7 of the 13 factors compared between the two stocks.